101 related articles for article (PubMed ID: 15951470)
41. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
Sarapa N; Britto MR; Mainka MB; Parivar K
Eur J Clin Pharmacol; 2005 Jun; 61(4):247-56. PubMed ID: 15887009
[TBL] [Abstract][Full Text] [Related]
42. Marked effect of liver and kidney function on the pharmacokinetics of selegiline.
Anttila M; Sotaniemi EA; Pelkonen O; Rautio A
Clin Pharmacol Ther; 2005 Jan; 77(1):54-62. PubMed ID: 15637531
[TBL] [Abstract][Full Text] [Related]
43. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.
Tenero D; Martin D; Chapelsky M; Ilson B; Boike S; Patterson S; Keogh J; Rodriguez S; Jorkasky D
Pharmacotherapy; 1998; 18(1):42-50. PubMed ID: 9469680
[TBL] [Abstract][Full Text] [Related]
44. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate.
Snell P; Dave N; Wilson K; Rowell L; Weil A; Galitz L; Robson R
Br J Clin Pharmacol; 2005 May; 59(5):598-601. PubMed ID: 15842560
[TBL] [Abstract][Full Text] [Related]
45. Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.
Khalilieh S; Yee KL; Liu R; Fan L; Sanchez RI; Auger P; Triantafyllou I; Stypinski D; Lasseter KC; Marbury T; Iwamoto M
J Clin Pharmacol; 2017 Jun; 57(6):777-783. PubMed ID: 28026013
[TBL] [Abstract][Full Text] [Related]
46. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
Bui K; She F; Sostek M
J Clin Pharmacol; 2014 Dec; 54(12):1368-74. PubMed ID: 24945932
[TBL] [Abstract][Full Text] [Related]
47. Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models.
Babu PR; Babu KN; Peter PL; Rajesh K; Babu PJ
Drug Dev Ind Pharm; 2013 Jun; 39(6):873-9. PubMed ID: 22817837
[TBL] [Abstract][Full Text] [Related]
48. [Pharmacokinetics of midazolam in patients with liver damage for hepatectomy].
Nishiyama T; Hirasaki A; Toda N; Iwasaki T; Konishi H; Seto K
Masui; 1993 Jun; 42(6):871-5. PubMed ID: 8320806
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
Itou M; Fujita T; Inoue K; Uchida N; Takagaki T; Ishii D; Kakuyama H
J Clin Pharmacol; 2020 Oct; 60(10):1397-1403. PubMed ID: 32437025
[TBL] [Abstract][Full Text] [Related]
50. Brivaracetam disposition in mild to severe hepatic impairment.
Stockis A; Sargentini-Maier ML; Horsmans Y
J Clin Pharmacol; 2013 Jun; 53(6):633-41. PubMed ID: 23649964
[TBL] [Abstract][Full Text] [Related]
51. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses.
Ferry N; Bernard N; Cuisinaud G; Rougier P; Trepo C; Sassard J
Fundam Clin Pharmacol; 1994; 8(5):463-73. PubMed ID: 7875642
[TBL] [Abstract][Full Text] [Related]
52. Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist.
Shakeri-Nejad K; Hoch M; Hoever P; Dingemanse J
Eur J Pharm Sci; 2013 Aug; 49(5):836-44. PubMed ID: 23770377
[TBL] [Abstract][Full Text] [Related]
53. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.
Everson G; Lasseter KC; Anderson KE; Bauer LA; Carithens RL; Wilner KD; Johnson A; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):21S-26S. PubMed ID: 10771450
[TBL] [Abstract][Full Text] [Related]
54. Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Trueman S; Mohamed MF; Feng T; Lacerda AP; Marbury T; Othman AA
J Clin Pharmacol; 2019 Sep; 59(9):1188-1194. PubMed ID: 30973649
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function.
Sane R; Malhi V; Sutaria DS; Cho E; Twomey P; Craggs C; Wang J; Harris A; Musib L
J Clin Pharmacol; 2022 Feb; 62(2):171-181. PubMed ID: 34402068
[TBL] [Abstract][Full Text] [Related]
56. Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration.
Corey AE; Agnew JR; King EC; Parekh NJ; Powell JH; Thompson GA
J Pharm Sci; 2004 May; 93(5):1279-86. PubMed ID: 15067704
[TBL] [Abstract][Full Text] [Related]
57. Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.
Jamieson BD; Ciric S; Fernandes P
Antimicrob Agents Chemother; 2015 Aug; 59(8):4379-86. PubMed ID: 25870056
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.
Keung AC; Eller MG; Weir SJ
J Clin Pharmacol; 1998 Jun; 38(6):517-24. PubMed ID: 9650541
[TBL] [Abstract][Full Text] [Related]
59. Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Scoville BA; Segal JH; Salama NN; Heung M; Bleske BE; Eyler RF; Mueller BA
Ren Fail; 2019 Nov; 41(1):118-125. PubMed ID: 30909832
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment.
Durnin C; Hind ID; Ghani SP; Yates DB; Molz KH
Proc West Pharmacol Soc; 2001; 44():83-4. PubMed ID: 11794005
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
